Li and colleagues conducted a study of 237 advanced NSCLC patients with EGFR mutations: 160 received immunotherapy in various combinations: ICI alone, ICI plus anti-angiogenesis, ICI plus chemotherapy, or ICI plus both anti-angiogenesis and chemotherapy [78]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.